<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30056" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Thiazolidinediones</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Eggleton</surname>
            <given-names>Julie S.</given-names>
          </name>
          <aff>California Northstate University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jialal</surname>
            <given-names>Ishwarlal</given-names>
          </name>
          <aff>VA MEDICAL CENTER, MATHER , CA</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Julie Eggleton declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ishwarlal Jialal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30056.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Thiazolidinediones are medications used to manage and treat type 2 diabetes mellitus. These medications may act as a nuclear transcription regulator and an insulin sensitizer. This activity illustrates the indications, mechanism of action, and contraindications for thiazolidinediones as valuable agents for managing type 2 diabetes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of thiazolidinediones.</p></list-item><list-item><p>Evaluate&#x000a0;the potential adverse effects of thiazolidinediones.</p></list-item><list-item><p>Assess&#x000a0;appropriate monitoring for the toxicity of thiazolidinediones.</p></list-item><list-item><p>Communicate&#x000a0;the importance of collaboration and coordination among the interprofessional team and how it can enhance patient care with thiazolidinedione therapy to improve patient outcomes for patients who have diabetes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30056&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30056">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30056.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Thiazolidinediones (TZDs), also called "glitazones," in managing&#x000a0;type 2 diabetes can help with glycemic control and insulin resistance.&#x000a0;There are&#x000a0;2 TZDs, rosiglitazone and pioglitazone, currently approved by the FDA as monotherapy or combined with metformin or sulfonylureas to manage type 2 diabetes mellitus. These medications should be combined with lifestyle modifications such as diet, exercise, and weight reduction.&#x000a0;TZDs may also be&#x000a0;used to treat polycystic ovarian syndrome, as these may lead to improved endothelial function, improved ovulation, and reduced insulin resistance.<xref ref-type="bibr" rid="article-30056.r1">[1]</xref>&#x000a0;Pioglitazone specifically reduces hepatic fat and may improve liver fibrosis in patients with nonalcoholic steatohepatitis; however, additional variables and risks require assessment in&#x000a0;nonalcoholic steatohepatitis patients.<xref ref-type="bibr" rid="article-30056.r2">[2]</xref><xref ref-type="bibr" rid="article-30056.r3">[3]</xref>&#x000a0;The most significant advantage of TZDs is that they do not cause hypoglycemia as monotherapy and are not contraindicated in patients with renal disease.&#x000a0;</p>
      </sec>
      <sec id="article-30056.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>TZDs are insulin sensitizers that act on intracellular metabolic pathways to enhance insulin action and increase insulin sensitivity in critical tissues.<xref ref-type="bibr" rid="article-30056.r4">[4]</xref>&#x000a0;TZDs also increase adiponectin levels, decrease hepatic gluconeogenesis, and increase insulin-dependent glucose uptake in muscle and fat. Adiponectin, a cytokine secreted by fat tissue, increases insulin sensitivity, and fatty acid oxidation increases with TZD therapy.<xref ref-type="bibr" rid="article-30056.r1">[1]</xref><xref ref-type="bibr" rid="article-30056.r5">[5]</xref><xref ref-type="bibr" rid="article-30056.r6">[6]</xref><xref ref-type="bibr" rid="article-30056.r7">[7]</xref>&#x000a0;</p>
        <p>TZDs regulate gene expression by binding to peroxisome proliferator-activated receptor-gamma (PPAR-gamma), a nuclear transcription regulator.<xref ref-type="bibr" rid="article-30056.r6">[6]</xref> Peroxisome proliferator-activated receptors (PPARs) are a family of ligand-activated transcription factors of nuclear hormone receptors that regulate energy homeostasis.&#x000a0;The genes activated by the PPAR-gamma&#x000a0;subtype are present in muscle, fat, and liver, regulating glucose metabolism, fatty acid storage, and adipocyte differentiation.<xref ref-type="bibr" rid="article-30056.r8">[8]</xref>&#x000a0;The binding of TZD induces a conformational change to alter gene expression of numerous pathways involved in metabolism regulation, including lipoprotein lipase, glucokinase, fatty acyl-CoA synthase, and others.<xref ref-type="bibr" rid="article-30056.r9">[9]</xref>&#x000a0; PPAR-gamma agonists improve insulin resistance by increasing adiponectin and GLUT4 expression and opposing the effect of TNF-alpha in adipocytes. Increased GLUT 4 expression increases glucose uptake in adipocytes and skeletal muscle cells in response to insulin.<xref ref-type="bibr" rid="article-30056.r8">[8]</xref></p>
        <p>In addition to their function in glycemic control and improvement of insulin resistance, TZDs potentially have anti-inflammatory and anti-cancer properties. There is evidence that TZDs may slow the progression of medial intimal thickening and decrease coronary intimal hyperplasia. Research has shown additional beneficial effects on endothelial function, atherogenesis, fibrinolysis, and ovarian steroidogenesis. Some studies demonstrated that activation of PPAR-gamma receptors could induce cancer cell apoptosis.&#x000a0;However, these mechanisms are still under investigation due to conflicting studies and possible confounders.<xref ref-type="bibr" rid="article-30056.r1">[1]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-30056.s4" sec-type="Administration">
        <title>Administration</title>
        <p>TZDs are taken orally once daily, with or without food. Before initiating treatment and periodically during therapy,&#x000a0;liver function tests and HbA1C levels require monitoring. Maximal glucose-lowering effects of TZDs are not seen for&#x000a0;6 weeks to 6 months due to a delayed onset of action via modification of gene expression. For&#x000a0;type 2 diabetes&#x000a0;management, TZDs should be combined with lifestyle modifications and combined with biguanides, sulfonylureas, and insulin injectables.<xref ref-type="bibr" rid="article-30056.r4">[4]</xref><xref ref-type="bibr" rid="article-30056.r10">[10]</xref>&#x000a0;</p>
        <p>Dosing for treatment of T2DM:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pioglitazone: Initial 15 to 30 mg PO with a meal once a day; may increase the dose by 15 mg with careful monitoring to 45 mg daily. The maximum dose is 45 mg.</p>
          </list-item>
          <list-item>
            <p>Rosiglitazone: Initial 4 mg PO once a day.&#x000a0;If there is an inadequate response after 8 to 12 weeks, the dose may be increased to 8 mg PO once a day&#x000a0;or 4 mg twice a day.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30056.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>There are several&#x000a0;undesirable side effects to TZDs, particularly with long-term use. The risks versus benefits require discussion with patients, and alternative first-line agents are attempted before using TZDs.&#x000a0;</p>
        <p><bold>Edema and Congestive Heart Failure</bold>&#x000a0;</p>
        <p>TZDs have been shown to cause dose-related fluid retention in up to 20% of patients. Methods of fluid retention include PPAR-gamma receptors in the distal nephron and insulin-activated epithelial sodium channels in the collecting tubules. PPAR-gamma activation stimulates sodium reabsorption, acting at the same site as aldosterone. Patients with preexisting edema or concomitant insulin therapy are at higher risk of edema and should start on the lowest available dose.<xref ref-type="bibr" rid="article-30056.r1">[1]</xref><xref ref-type="bibr" rid="article-30056.r4">[4]</xref><xref ref-type="bibr" rid="article-30056.r11">[11]</xref> In most patients, fluid retention responds to diuretics such as thiazides or spironolactone if the edema is mild or loop diuretics for severe cases. Furthermore, lower doses of 15 and 30 mg daily decrease the risk of edema and weight gain.</p>
        <p>There are reports of an increase in intravascular volume to the point of congestive heart failure. Thus, TZDs should be used with caution in patients with diastolic dysfunction or a history of CHF. The risk of heart failure and death is higher in rosiglitazone than in pioglitazone.<xref ref-type="bibr" rid="article-30056.r12">[12]</xref></p>
        <p>
<bold>Weight Gain</bold>
</p>
        <p>Adipocytes have the highest concentration of PPAR-gamma receptors in the body. The mechanism behind weight gain is a combination of factors. TZDs upregulate PPAR-gamma receptors in the central nervous system, leading to increased feeding. TZD agents expand adipose tissue mass via the maturation of preadipocytes into mature adipocytes and increase fat storage by increasing free fatty acid movement into cells. Additionally, fluid retention can increase weight.<xref ref-type="bibr" rid="article-30056.r4">[4]</xref><xref ref-type="bibr" rid="article-30056.r13">[13]</xref> Fat gain occurs primarily in the subcutaneous tissues, sparing the visceral area.&#x000a0;As with edema and CHF, weight gain becomes exacerbated by concomitant insulin use, but the risk decreases when&#x000a0;using metformin and lower doses of TZDs.</p>
        <p>
<bold>Fractures</bold>
</p>
        <p>Several studies have demonstrated an increased fracture risk and decreased bone density in patients taking TZDs compared to those taking insulin or other oral agents such as sulfonylureas. Proposed mechanisms for this include PPAR-gamma activation and insulin-like growth factor down-regulation, which diverts the differentiation of osteoblasts into adipocytes and leads to bone loss.<xref ref-type="bibr" rid="article-30056.r1">[1]</xref><xref ref-type="bibr" rid="article-30056.r14">[14]</xref> These fractures appear more likely in the distal extremities (forearm, wrist, ankle, foot, tibia) than the axial skeleton (hip, pelvis, femur). The fracture risk is further increased by additional risk factors, such as postmenopausal females or patients concurrently taking glucocorticoids or proton pump inhibitors.<xref ref-type="bibr" rid="article-30056.r15">[15]</xref><xref ref-type="bibr" rid="article-30056.r16">[16]</xref><xref ref-type="bibr" rid="article-30056.r17">[17]</xref></p>
        <p>
<bold>Bladder Cancer</bold>
</p>
        <p>Pioglitazone&#x000a0;has, in some studies, shown correlations with an increased risk of bladder cancer. This effect varies in a duration-dependent and dose-dependent fashion. Also, most recent analyses do not support an increased risk. In contrast, rosiglitazone was not associated with an increased risk of bladder cancer in any analysis, suggesting the risk is drug-specific and not a class effect.<xref ref-type="bibr" rid="article-30056.r18">[18]</xref></p>
        <p>
<bold>Hepatotoxicity</bold>
</p>
        <p>Troglitazone, the original PPAR-gamma activator, was removed from the market primarily due to hepatotoxicity. However, the other agents, rosiglitazone and pioglitazone, have rarely been linked to acute liver injury.<xref ref-type="bibr" rid="article-30056.r5">[5]</xref><xref ref-type="bibr" rid="article-30056.r10">[10]</xref> Baseline and routine monitoring of alanine aminotransferase levels and monitoring for clinical symptoms of liver injury are recommended.<xref ref-type="bibr" rid="article-30056.r19">[19]</xref><xref ref-type="bibr" rid="article-30056.r20">[20]</xref><xref ref-type="bibr" rid="article-30056.r21">[21]</xref></p>
        <p>
<bold>Diabetic Macular Edema</bold>
</p>
        <p>A combination of TZD and insulin therapy has correlated with an increased incidence of diabetic macular edema at 1-year and 10-year follow-ups. However, more studies are&#x000a0;underway to evaluate confounding factors and define the frequency of this adverse event.<xref ref-type="bibr" rid="article-30056.r22">[22]</xref><xref ref-type="bibr" rid="article-30056.r23">[23]</xref></p>
        <p>
<bold>Increased Ovulation and Teratogenic Effects</bold>
</p>
        <p>Patients with polycystic ovarian syndrome have shown an increased ovulation rate when using TZD and other insulin sensitizers. This effect may result in ovulation in some premenopausal, anovulatory women, leading to improved rates of spontaneous pregnancy. However, TZDs have also been shown to have some teratogenic potential by decreasing fetal maturation. Premenopausal women should use contraception if they are not trying to conceive and switch to another insulin sensitizer, such as metformin, after conception.<xref ref-type="bibr" rid="article-30056.r24">[24]</xref></p>
      </sec>
      <sec id="article-30056.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>When considering management for T2DM, primary interventions should be lifestyle changes such as diet, exercise, and weight reduction. Due to their favorable side effect profiles, metformin or sulfonylureas should be the first-line monotherapy. However, TZDs may be used as monotherapy or as combination therapy when first-line medications are contraindicated. TZDs may be necessary for high-risk hypoglycemic patients; however, the contraindications require evaluation before starting treatment.</p>
        <p>There are several contraindications for using TZDs, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Heart failure (New York Heart Association class III, IV): The American Heart Association and the American Diabetes Association have stated that patients with New York Heart Association class III, IV symptomatic heart failure should use TZD at the lowest possible dose or not at all due to risk of fluid retention and diastolic heart dysfunction.<xref ref-type="bibr" rid="article-30056.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Moderate to severe hepatic impairment: Troglitazone was removed from the market due to hepatoxicity. While rosiglitazone or pioglitazone have not shown the same hepatotoxic effects, the recommendation is that patients undergo baseline and periodic monitoring of liver function. Patients with AST or ALT greater than or equal to 3 times the upper reference limit should discontinue TZD therapy.<xref ref-type="bibr" rid="article-30056.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Bladder cancer: Pioglitazone should not be used in patients with active bladder cancer. In patients with a history of bladder cancer, the risk of recurrence versus the benefits of glycemic control should&#x000a0;merit consideration before starting pioglitazone treatment. Rosiglitazone has not shown similar risks of bladder cancer.<xref ref-type="bibr" rid="article-30056.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p>Pregnancy: The FDA labels TZDs as pregnancy class C with teratogenic potential, as PPAR-gamma is necessary for terminal differentiation of the trophoblast and placental vascularization. Pregnant patients should switch to another insulin sensitizer, such as metformin.<xref ref-type="bibr" rid="article-30056.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p>High risk of fractures: Due to increased fracture risk, patients who are at a high risk of fractures, such as those with a history of osteoporosis, postmenopausal women, or patients taking other medications that increase fracture risk (such as glucocorticoids and proton pump inhibitors), should not start on TZD therapy.<xref ref-type="bibr" rid="article-30056.r1">[1]</xref><xref ref-type="bibr" rid="article-30056.r14">[14]</xref><xref ref-type="bibr" rid="article-30056.r15">[15]</xref><xref ref-type="bibr" rid="article-30056.r16">[16]</xref><xref ref-type="bibr" rid="article-30056.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Cytochromes CYP 2C8 and CYP 3A4 are necessary for the metabolism of TZDs; therefore, cytochrome inducers and inhibitors should be used with caution, as these medications may affect the drug plasma levels of TZDs.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30056.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients should have liver function tests evaluated before beginning TZD therapy and periodically during treatment. If&#x000a0;liver function tests&#x000a0;exceed or equal to 3 times the upper limit, then TZD should not be started or discontinued. Additionally, physicians should monitor for clinical symptoms of hepatic injury, such as jaundice or dark urine.<xref ref-type="bibr" rid="article-30056.r10">[10]</xref> Clinicians need to monitor patients&#x02019; body weight to detect possible fluid overload. Signs and symptoms of fluid overload or heart failure, such as rapid weight gain, peripheral edema, dyspnea, S3 heart sounds, or decreased ejection fraction, require close monitoring. HbA1c should be monitored at least twice yearly to assess glycemic control and consider dosage adjustments.<xref ref-type="bibr" rid="article-30056.r13">[13]</xref><xref ref-type="bibr" rid="article-30056.r26">[26]</xref></p>
      </sec>
      <sec id="article-30056.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The use of&#x000a0;TZDs in the management of T2DM requires an interprofessional healthcare team. These agents can help with glycemic control and insulin resistance in patients with functional pancreatic beta-cells. Though they are not first-line agents, they can act synergistically with other oral agents and insulin. They modify gene transcription to increase adiponectin and insulin sensitivity, lower plasma glucose by increasing glucose utilization, decrease plasma fatty acids by increasing fatty acid oxidation, decrease serum triglycerides and decrease visceral fat. Early use of TZDs during the disease may benefit the pancreas, but many long-term dose and duration-dependent adverse effects limit their use. Such effects may include heart failure,&#x000a0; weight gain, and bone density loss.</p>
        <p>When properly prescribed and carefully monitored, they can effectively&#x000a0;reduce fasting plasma glucose and HbA1c levels in some patients by increasing insulin sensitivity. These adverse effects are why a pharmacist consult may be necessary to verify the dosing regimen, check for interactions, and perform medication reconciliation. To receive maximum benefit from TZDs, patient body weight, liver function, plasma glucose, and HbA1c levels need monitoring at follow-up visits; these are functions a diabetes nurse educator can perform and keep the prescriber informed regarding progress. In addition to being used as adjunctive therapy for diabetes, they have a place in patients with steatohepatitis since they reduce liver fat in clinical trials. With an appropriate interprofessional team approach to thiazolidinedione therapy, patient outcomes for type 2 diabetes can improve with minimal adverse events.</p>
      </sec>
      <sec id="article-30056.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30056&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30056">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30056/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30056">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30056.s10">
        <title>References</title>
        <ref id="article-30056.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yau</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rivera</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lomonaco</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cusi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus.</article-title>
            <source>Curr Diab Rep</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>329</fpage>
            <page-range>329-41</page-range>
            <pub-id pub-id-type="pmid">23625197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Musso</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cassader</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Paschetta</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gambino</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.</article-title>
            <source>JAMA Intern Med</source>
            <year>2017</year>
            <month>May</month>
            <day>01</day>
            <volume>177</volume>
            <issue>5</issue>
            <fpage>633</fpage>
            <page-range>633-640</page-range>
            <pub-id pub-id-type="pmid">28241279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>He</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>95</volume>
            <issue>42</issue>
            <fpage>e4947</fpage>
            <pub-id pub-id-type="pmid">27759627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamanouchi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes.</article-title>
            <source>Vasc Health Risk Manag</source>
            <year>2010</year>
            <month>Apr</month>
            <day>15</day>
            <volume>6</volume>
            <fpage>189</fpage>
            <page-range>189-97</page-range>
            <pub-id pub-id-type="pmid">20407626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r5">
          <label>5</label>
          <element-citation publication-type="book">
            <chapter-title>Antidiabetic Agents</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>6</month>
            <day>6</day>
            <pub-id pub-id-type="pmid">31644090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vieira</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Souto</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-L&#x000f3;pez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Machado</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Severino</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jose</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Santini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fortuna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Souto</surname>
                <given-names>EB</given-names>
              </name>
            </person-group>
            <article-title>Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Review of Classical and New Compounds: Part-I.</article-title>
            <source>Pharmaceuticals (Basel)</source>
            <year>2019</year>
            <month>Oct</month>
            <day>10</day>
            <volume>12</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">31658729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gor</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gerber</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Walton</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Nutescu</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Touchette</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Antidiabetic drug use trends in patients with type 2 diabetes mellitus and chronic kidney disease: A cross-sectional analysis of the National Health and Nutrition Examination Survey.</article-title>
            <source>J Diabetes</source>
            <year>2020</year>
            <month>May</month>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>385</fpage>
            <page-range>385-395</page-range>
            <pub-id pub-id-type="pmid">31652390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tyagi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Saini</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Kaushal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases.</article-title>
            <source>J Adv Pharm Technol Res</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>236</fpage>
            <page-range>236-40</page-range>
            <pub-id pub-id-type="pmid">22247890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Revisiting PPAR&#x003b3; as a target for the treatment of metabolic disorders.</article-title>
            <source>BMB Rep</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>47</volume>
            <issue>11</issue>
            <fpage>599</fpage>
            <page-range>599-608</page-range>
            <pub-id pub-id-type="pmid">25154720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Floyd</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Barbehenn</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lurie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wolfe</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Case series of liver failure associated with rosiglitazone and pioglitazone.</article-title>
            <source>Pharmacoepidemiol Drug Saf</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>18</volume>
            <issue>12</issue>
            <fpage>1238</fpage>
            <page-range>1238-43</page-range>
            <pub-id pub-id-type="pmid">19623674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DeFronzo</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>The effect of insulin on renal sodium metabolism. A review with clinical implications.</article-title>
            <source>Diabetologia</source>
            <year>1981</year>
            <month>Sep</month>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>165</fpage>
            <page-range>165-71</page-range>
            <pub-id pub-id-type="pmid">7028550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Juurlink</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Gomes</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lipscombe</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Austin</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Hux</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Mamdani</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study.</article-title>
            <source>BMJ</source>
            <year>2009</year>
            <month>Aug</month>
            <day>18</day>
            <volume>339</volume>
            <fpage>b2942</fpage>
            <pub-id pub-id-type="pmid">19690342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yki-J&#x000e4;rvinen</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Thiazolidinediones.</article-title>
            <source>N Engl J Med</source>
            <year>2004</year>
            <month>Sep</month>
            <day>09</day>
            <volume>351</volume>
            <issue>11</issue>
            <fpage>1106</fpage>
            <page-range>1106-18</page-range>
            <pub-id pub-id-type="pmid">15356308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ali</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Parfitt</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Manolagas</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Jilka</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.</article-title>
            <source>Endocrinology</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>146</volume>
            <issue>3</issue>
            <fpage>1226</fpage>
            <page-range>1226-35</page-range>
            <pub-id pub-id-type="pmid">15591153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dormuth</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Carney</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Carleton</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bassett</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Thiazolidinediones and fractures in men and women.</article-title>
            <source>Arch Intern Med</source>
            <year>2009</year>
            <month>Aug</month>
            <day>10</day>
            <volume>169</volume>
            <issue>15</issue>
            <fpage>1395</fpage>
            <page-range>1395-402</page-range>
            <pub-id pub-id-type="pmid">19667303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bilik</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McEwen</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Pomeroy</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Asao</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Crosson</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Duru</surname>
                <given-names>OK</given-names>
              </name>
              <name>
                <surname>Ferrara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hsiao</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Karter</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Marrero</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Selby</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Subramanian</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Herman</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Thiazolidinediones and fractures: evidence from translating research into action for diabetes.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>95</volume>
            <issue>10</issue>
            <fpage>4560</fpage>
            <page-range>4560-5</page-range>
            <pub-id pub-id-type="pmid">20631021</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kraenzlin</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Bodmer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jick</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Jick</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Meier</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Use of thiazolidinediones and fracture risk.</article-title>
            <source>Arch Intern Med</source>
            <year>2008</year>
            <month>Apr</month>
            <day>28</day>
            <volume>168</volume>
            <issue>8</issue>
            <fpage>820</fpage>
            <page-range>820-5</page-range>
            <pub-id pub-id-type="pmid">18443256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dormandy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bhattacharya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Troostenburg de Bruyn</surname>
                <given-names>AR</given-names>
              </name>
              <collab>PROactive investigators</collab>
            </person-group>
            <article-title>Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive.</article-title>
            <source>Drug Saf</source>
            <year>2009</year>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>187</fpage>
            <page-range>187-202</page-range>
            <pub-id pub-id-type="pmid">19338377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r19">
          <label>19</label>
          <element-citation publication-type="book">
            <chapter-title>Pioglitazone</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>6</month>
            <day>6</day>
            <pub-id pub-id-type="pmid">31643649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r20">
          <label>20</label>
          <element-citation publication-type="book">
            <chapter-title>Rosiglitazone</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>6</month>
            <day>6</day>
            <pub-id pub-id-type="pmid">31643444</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lebovitz</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Kreider</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Freed</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.</article-title>
            <source>Diabetes Care</source>
            <year>2002</year>
            <month>May</month>
            <volume>25</volume>
            <issue>5</issue>
            <fpage>815</fpage>
            <page-range>815-21</page-range>
            <pub-id pub-id-type="pmid">11978674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Idris</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Donnelly</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes.</article-title>
            <source>Arch Intern Med</source>
            <year>2012</year>
            <month>Jul</month>
            <day>09</day>
            <volume>172</volume>
            <issue>13</issue>
            <fpage>1005</fpage>
            <page-range>1005-11</page-range>
            <pub-id pub-id-type="pmid">22688528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fong</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Contreras</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Glitazone use associated with diabetic macular edema.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>147</volume>
            <issue>4</issue>
            <fpage>583</fpage>
            <page-range>583-586.e1</page-range>
            <pub-id pub-id-type="pmid">19181303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Froment</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Touraine</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Thiazolidinediones and Fertility in Polycystic Ovary Syndrome (PCOS).</article-title>
            <source>PPAR Res</source>
            <year>2006</year>
            <volume>2006</volume>
            <fpage>73986</fpage>
            <pub-id pub-id-type="pmid">17347533</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scheen</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Hepatotoxicity with thiazolidinediones: is it a class effect?</article-title>
            <source>Drug Saf</source>
            <year>2001</year>
            <volume>24</volume>
            <issue>12</issue>
            <fpage>873</fpage>
            <page-range>873-88</page-range>
            <pub-id pub-id-type="pmid">11735645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30056.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahn</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Haffner</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Heise</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Herman</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Holman</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Kravitz</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Lachin</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Zinman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Viberti</surname>
                <given-names>G</given-names>
              </name>
              <collab>ADOPT Study Group</collab>
            </person-group>
            <article-title>Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.</article-title>
            <source>N Engl J Med</source>
            <year>2006</year>
            <month>Dec</month>
            <day>07</day>
            <volume>355</volume>
            <issue>23</issue>
            <fpage>2427</fpage>
            <page-range>2427-43</page-range>
            <pub-id pub-id-type="pmid">17145742</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
